What does the research say about inositol?

The short answer

For women with PCOS, inositol appears to help ovulation and blood sugar. Whether it leads to more pregnancies or babies is genuinely unclear.

What to know

The clearer signal is for ovulation and insulin measures, not for births.
Trials are small and use different doses and formulations, so results are hard to combine.
Usually well tolerated; stomach upset is the common complaint at higher doses.
Worth asking where it sits relative to letrozole or metformin for you.

Safety and interactions. Generally well tolerated; gastrointestinal upset at higher doses is the common complaint.

Read the full explanation

If you have PCOS

Strong evidence The first-line medical treatment for ovulation in PCOS is letrozole, according to the 2023 international PCOS guideline. Metformin is another option. Inositol shouldn't delay either.
If you want to try inositol, the dose in the classic trial was 4 g of myo-inositol a day (often taken as 2 g twice daily), alongside folic acid.
The popular 40:1 ratio of myo-inositol to D-chiro-inositol hasn't been shown to beat other forms.
It tends to cause fewer stomach side effects than metformin.

What the evidence is based on

In a 2007 trial of 92 women with PCOS, myo-inositol increased ovulation (25% of cycles vs 15%) and shortened the time to first ovulation; it didn't work in women with a BMI over 37. The analysis commissioned for the 2023 guideline, covering 30 trials, found the evidence "limited and inconclusive", and the guideline calls inositol experimental for fertility. Reasonable to discuss — not a replacement for proven treatment.

What the research shows

Does myo-inositol improve fertility outcomes for women with PCOS?

Limited or mixed Conditionally supported

Studies disagree, or the answer changes depending on the situation.

Who was studied. Women with polycystic ovary syndrome and subfertility.

Outcome measured. Ovulation — a marker, not a birth outcome

What was found. Evidence suggests improvement in ovulation and metabolic markers such as insulin resistance. For live birth, a Cochrane review judged the evidence too uncertain to draw a conclusion.

Main limitation. Small trials using different doses and formulations, with live birth poorly measured.

Why this rating?

The signal is stronger for the intermediate outcomes (ovulation, insulin measures) than for pregnancy or live birth, and the trials are small with varied doses and formulations. Rated low rather than moderate because the outcome that matters most is the one the evidence is thinnest on.

How we grade evidence

Questions for your doctor

Edit any of these before you add it — they're yours. Your list stays in this browser, and you can print a one-page sheet from it.

I have PCOS — where does inositol sit relative to letrozole or metformin for me?
Would you combine them, or try one first?

My question list (0)

Sources

Editorial status. Written and edited September 2026 · every citation on this page opened and checked against the claim it supports, September 2026 · not reviewed by a clinician. We say that plainly because it matters: this is researched and sourced writing, not a medically reviewed publication. Take it to someone who knows your history.

The Onward Babe newsletter

What's Next

One email a month: the latest research, rated · real stories from every stage · the products and tools worth knowing about. Free.

We save your email address and nothing else — not your Path, not your answers. It's sent with Kit. One click unsubscribes, and we never sell or share it. What we do with it.

Onward Babe is educational, not medical advice. Everything here is built from published research and professional guidelines so you can have a better conversation with the doctor who actually knows your situation.